NCT05630638View on ClinicalTrials.gov

Doravirine Dose Optimisation in Pregnancy

PHASE4RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

October 10, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

February 28, 2026

Conditions
HIV
Interventions
DRUG

Doravirine

Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil

DRUG

Dolutegravir

Fixed dose combination of dolutegravir, lamivudine and tenofovir disoproxil

Trial Locations (1)

Unknown

RECRUITING

Desmond Tutu Health Foundation, Cape Town

All Listed Sponsors
collaborator

Liverpool School of Tropical Medicine

OTHER

collaborator

Desmond Tutu Health Foundation

OTHER

lead

University of Liverpool

OTHER